# COSINR (NCT03223155)

> Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab plus stereotactic body radiotherapy
- Indication: stage IV non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03223155
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Chicago
- Conditions: Stage IV Small Cell Lung Cancer
- Interventions: Nivolumab; Ipilimumab; Stereotactic body radiation therapy
- Enrollment: 78
- Primary outcome: Number of serious adverse events

## Indexed commentary on COSINR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 13

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=cosinr-nct03223155

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03223155", "email": "<work email>"}; the inbox owner confirms by the emailed link.